# Notice of Funding Opportunity (NOFO) PS22-2209: Transgender Status-Neutral Communityto-Clinic Models to End the HIV Epidemic (TRANSCEND)

HIV Research Branch
Division of HIV Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

January 19, 2022



# Purpose of Today's Call

- Provide an overview of our new NOFO PS22-2209: TRANSCEND
- Q&A
- Recorded and posted



# Background

- TG persons, especially transgender women (TGW), have a high prevalence of HIV and lifetime risk of acquiring HIV.
- Despite the disproportionate burden of HIV among TGW, receipt of HIV prevention and care services have been suboptimal.
- Many TG persons seek hormone therapy at TG clinics that serve as centers of excellence for TG health and well-being.
  - These encounters provide opportunities for HIV education and counseling, HIV testing and risk assessment, status-neutral HIV services, STI testing, and other health care services.

# Purpose

- Fund organizations to develop community-to-clinic models of outreach to TG persons and navigation to TG clinics for integrated status-neutral HIV prevention and care services, gender-affirming services including hormone therapy, and primary health care.
  - Status-neutral programs use the same approach for engagement in HIV prevention and HIV care services, to provide linkage, support, or clinical care regardless of the results of an HIV test.
- Models will increase use of HIV prevention and treatment services and other health care services by TG persons to decrease HIV transmission and improve overall health and wellbeing.

# **Priority Population**

- Focus activities among transgender women, especially Black and Hispanic TGW.
  - TG persons living in the 50 jurisdictions included in Phase 1 of the Ending the HIV Epidemic in the U.S. (EHE) initiative.



(<a href="https://ahead.hiv.gov/">https://ahead.hiv.gov/</a>)

## **Award Information**

Type of Award	Cooperative Agreement
Fiscal Year Funds	2022
Approximate Annual Funding	\$2,000,000
Approximate Number or Awards	4
Average Annual Award	\$500,000
Budget Period/Length	12 months
Project Period	4 years: May 2022 – May 2026

<sup>\*</sup>Subject to the availability of funds



- Provide integrated HIV testing, status-neutral HIV prevention and care services, & comprehensive TG health services to TG persons through TG CBO and clinic collaboratives
  - Develop collaborations between TG clinics, TG CBOs, and HIV clinics
  - Conduct HIV testing in TG CBOs and clinics
  - Provide status-neutral HIV prevention and care services in TG clinics, as well as comprehensive health services

- Support use of mental health and substance use disorder services
   & other essential support services by TG persons
  - Identify service providers in the community
  - Identify needs and support linkage to services

- Provide services that are culturally and linguistically sensitive for TG persons, especially for Black and Hispanic persons
  - Provide TG cultural awareness training for all CBO and clinic staff
  - Recruit project staff with experience in providing care for TG persons

 Participate in a national learning collaborative to share best practices and lessons learned for community-to-care, statusneutral, comprehensive HIV & other services for TG persons

### Collaboration

- Recipients that are TG clinics are required to collaborate with local TG CBOs and with state or local health departments in their jurisdiction.
- Recipients may provide up to 20% of their award to the collaborating TG CBO(s).
- Recipients are required to obtain MOUs/MOAs from CBOs and health departments as evidence for the collaboration.



# Eligibility

- Unrestricted, open to any type of entity
- Additional information on eligibility
  - Applicants must have a history of providing clinical services to TG persons, or must have a history of working with an organization that provides clinical services to TG persons, including gender affirming hormone therapy

# Applicants should demonstrate:

- Capacity for program and evaluation, performance monitoring, financial reporting, budget management, and personnel management.
  - Ability to collect person-level longitudinal clinical data using EHR and data collection systems.
- Relevant experience and capacity to implement the activities and achieve the project outcomes for the priority population.
  - Experience and credibility in providing clinical services to TG persons consistently for at least the last 24 months, with experience in providing gender-affirming hormone therapy and other healthcare services for TG persons, especially Black and Hispanic TGW.
  - Provision of clinical services for at least 100 TGW in 2019, serving a population comprised of at least 50% Black or Hispanic TG persons.
  - For applicants that are not TG clinics, a letter from the partnering TG clinic indicating their support of the application and plans to implement proposed activities is required.

# Application Review and Selection Process

### Phase I: Eligibility Review

 CDC Office of Grants Services reviews all application for eligibility and completeness

### Phase II: Objective Review Panels

- Applications will be reviewed and scored by an independent review panel assigned by CDC and evaluated based on the scoring criteria outlined in the NOFO including applicant's approach, evaluation and performance measurement, and organizational capacity
- Phase III: Final funding determinations will be based on application scores from the Objective Review and CDC's funding preferences

# Important Dates

- Letter of Intent (LOI): 1/31/2022 (optional)
- Due date for applications: 2/25/2022 at 11:59 pm EST

### Website & Contact Information for PS22-2209

- Website
  - https://www.cdc.gov/hiv/funding/announcements/ps22-2209/index.html
  - FAQs coming soon to the website
- Program staff: Anne Kimball, Kashif Iqbal, Dejené Parrish, Damian Denson, Karen Hoover
  - Email: <u>HRBNOFO@cdc.gov</u>
- Office of Grants Services: Edna Green
  - Email: ecg4@cdc.gov

# **THANK YOU!**

Q&A

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention

